Targeting MLL1 H3K4 Methyltransferase Activity in Mixed-Lineage Leukemia

Molecular Cell

Volumn 53, Issue 2, 2014, Pages 247-261

  Cao, Fang ^a   Townsend, Elizabeth C ^a,h   Karatas, Hacer ^a,b   Xu, Jing ^a   Li, Li ^c   Lee, Shirley ^a   Liu, Liu ^a,b,i   Chen, Yong ^d   Ouillette, Peter ^a,b   Zhu, Jidong ^e   Hess, Jay L ^f   Atadja, Peter ^g   Lei, Ming ^a,d   Qin, Zhaohui S ^c   Malek, Sami ^a,b   Wang, Shaomeng ^a,b   Dou, Yali ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c EMORY UNIVERSITY   (United States)

^d INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^e INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g ACM Research (Shanghai) Inc   (China)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ EPFL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE H3; HISTONE METHYLTRANSFERASE; HISTONE METHYLTRANSFERASE MLL1; METHYLTRANSFERASE; METHYLTRANSFERASE INHIBITOR; MIXED LINEAGE LEUKEMIA PROTEIN; MM 401; PROTEIN BCL 2; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; BLAST CELL; BONE MARROW CELL; CANCER INHIBITION; CELL CYCLE ARREST; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; ENANTIOMER; ENZYME ACTIVITY; ENZYME INHIBITION; GENE DELETION; GENE EXPRESSION; HISTONE METHYLATION; LEUKEMIA CELL LINE; MOUSE; NONHUMAN; ONCOGENE C MYC; PROTEIN INTERACTION; PROTEIN STRUCTURE; TOXICITY;

ANIMALS; APOPTOSIS; CELL CYCLE CHECKPOINTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; HISTONE-LYSINE N-METHYLTRANSFERASE; HISTONES; HUMANS; LEUKEMIA, BIPHENOTYPIC, ACUTE; MICE; MYELOID-LYMPHOID LEUKEMIA PROTEIN; OLIGOPEPTIDES; PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TRANSCRIPTOME;

EID: 84892841527     PISSN: 10972765     EISSN: 10974164     Source Type: Journal    
DOI: 10.1016/j.molcel.2013.12.001     Document Type: Article

References (49)

1. Artinger E.L., Mishra B.P., Zaffuto K.M., Li B.E., Chung E.K., Moore A.W., Chen Y., Cheng C., Ernst P. An MLL-dependent network sustains hematopoiesis. Proc. Natl. Acad. Sci. USA 2013, 110:12000-12005.
2. Ayton P.M., Cleary M.L. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 2001, 20:5695-5707.
3. Bernt K.M., Armstrong S.A. Targeting epigenetic programs in MLL-rearranged leukemias. Hematology (Am Soc Hematol Educ Program) 2011, 2011:354-360.
4. Bernt K.M., Zhu N., Sinha A.U., Vempati S., Faber J., Krivtsov A.V., Feng Z., Punt N., Daigle A., Bullinger L., et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011, 20:66-78.
5. Cao F., Chen Y., Cierpicki T., Liu Y., Basrur V., Lei M., Dou Y. An Ash2L/RbBP5 heterodimer stimulates the MLL1 methyltransferase activity through coordinated substrate interactions with the MLL1 SET domain. PLoS ONE 2010, 5:e14102.
6. Cho Y.W., Hong T., Hong S., Guo H., Yu H., Kim D., Guszczynski T., Dressler G.R., Copeland T.D., Kalkum M., Ge K. PTIP associates with MLL3- and MLL4-containing histone H3 lysine 4 methyltransferase complex. J. Biol. Chem. 2007, 282:20395-20406.
7. Cosgrove M.S., Patel A. Mixed lineage leukemia: a structure-function perspective of the MLL1 protein. FEBS J. 2010, 277:1832-1842.
8. Daigle S.R., Olhava E.J., Therkelsen C.A., Majer C.R., Sneeringer C.J., Song J., Johnston L.D., Scott M.P., Smith J.J., Xiao Y., et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011, 20:53-65.
9. Dawson M.A., Prinjha R.K., Dittmann A., Giotopoulos G., Bantscheff M., Chan W.I., Robson S.C., Chung C.W., Hopf C., Savitski M.M., et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011, 478:529-533.
10. Delmore J.E., Issa G.C., Lemieux M.E., Rahl P.B., Shi J., Jacobs H.M., Kastritis E., Gilpatrick T., Paranal R.M., Qi J., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146:904-917.
11. Dou Y., Hess J.L. Mechanisms of transcriptional regulation by MLL and its disruption in acute leukemia. Int. J. Hematol. 2008, 87:10-18.
12. Dou Y., Milne T.A., Tackett A.J., Smith E.R., Fukuda A., Wysocka J., Allis C.D., Chait B.T., Hess J.L., Roeder R.G. Physical association and coordinate function of the H3 K4 methyltransferase MLL1 and the H4 K16 acetyltransferase MOF. Cell 2005, 121:873-885.
13. Dou Y., Milne T.A., Ruthenburg A.J., Lee S., Lee J.W., Verdine G.L., Allis C.D., Roeder R.G. Regulation of MLL1 H3K4 methyltransferase activity by its core components. Nat. Struct. Mol. Biol. 2006, 13:713-719.
14. Grembecka J., He S., Shi A., Purohit T., Muntean A.G., Sorenson R.J., Showalter H.D., Murai M.J., Belcher A.M., Hartley T., et al. Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia. Nat. Chem. Biol. 2012, 8:277-284.
15. Guenther M.G., Jenner R.G., Chevalier B., Nakamura T., Croce C.M., Canaani E., Young R.A. Global and Hox-specific roles for the MLL1 methyltransferase. Proc. Natl. Acad. Sci. USA 2005, 102:8603-8608.
16. Hess J.L., Yu B.D., Li B., Hanson R., Korsmeyer S.J. Defects in yolk sac hematopoiesis in Mll-null embryos. Blood 1997, 90:1799-1806.
17. Hughes C.M., Rozenblatt-Rosen O., Milne T.A., Copeland T.D., Levine S.S., Lee J.C., Hayes D.N., Shanmugam K.S., Bhattacharjee A., Biondi C.A., et al. Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol. Cell 2004, 13:587-597.
18. Jo S.Y., Granowicz E.M., Maillard I., Thomas D., Hess J.L. Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation. Blood 2011, 117:4759-4768.
19. Jude C.D., Climer L., Xu D., Artinger E., Fisher J.K., Ernst P. Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors. Cell Stem Cell 2007, 1:324-337.
20. Karatas H., Townsend E.C., Cao F., Chen Y., Bernard D., Liu L., Lei M., Dou Y., Wang S. High-affinity, small-molecule peptidomimetic inhibitors of MLL1/WDR5 protein-protein interaction. J. Am. Chem. Soc. 2013, 135:669-682.
21. Kentsis A., Look A.T. Distinct and dynamic requirements for mTOR signaling in hematopoiesis and leukemogenesis. Cell Stem Cell 2012, 11:281-282.
22. Krivtsov A.V., Armstrong S.A. MLL translocations, histone modifications and leukaemia stem-cell development. Nat. Rev. Cancer 2007, 7:823-833.
23. Krivtsov A.V., Feng Z., Lemieux M.E., Faber J., Vempati S., Sinha A.U., Xia X., Jesneck J., Bracken A.P., Silverman L.B., et al. H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 2008, 14:355-368.
24. Lauberth S.M., Nakayama T., Wu X., Ferris A.L., Tang Z., Hughes S.H., Roeder R.G. H3K4me3 interactions with TAF3 regulate preinitiation complex assembly and selective gene activation. Cell 2013, 152:1021-1036.
25. Li X., Wu L., Corsa C.A., Kunkel S., Dou Y. Two mammalian MOF complexes regulate transcription activation by distinct mechanisms. Mol. Cell 2009, 36:290-301.
26. Lin C., Smith E.R., Takahashi H., Lai K.C., Martin-Brown S., Florens L., Washburn M.P., Conaway J.W., Conaway R.C., Shilatifard A. AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol. Cell 2010, 37:429-437.
27. Liu H., Takeda S., Cheng E.H., Hsieh J.J. Biphasic MLL takes helm at cell cycle control: implications in human mixed lineage leukemia. Cell Cycle 2008, 7:428-435.
28. McMahon K.A., Hiew S.Y.L., Hadjur S., Veiga-Fernandes H., Menzel U., Price A.J., Kioussis D., Williams O., Brady H.J.M. Mll has a critical role in fetal and adult hematopoietic stem cell self-renewal. Cell Stem Cell 2007, 1:338-345.
29. Milne T.A., Briggs S.D., Brock H.W., Martin M.E., Gibbs D., Allis C.D., Hess J.L. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol. Cell 2002, 10:1107-1117.
30. Milne T.A., Kim J., Wang G.G., Stadler S.C., Basrur V., Whitcomb S.J., Wang Z., Ruthenburg A.J., Elenitoba-Johnson K.S., Roeder R.G., Allis C.D. Multiple interactions recruit MLL1 and MLL1 fusion proteins to the HOXA9 locus in leukemogenesis. Mol. Cell 2010, 38:853-863.
31. Monroe S.C., Jo S.Y., Sanders D.S., Basrur V., Elenitoba-Johnson K.S., Slany R.K., Hess J.L. MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia. Exp. Hematol. 2011, 39:77-86. e1-e5.
32. Mueller D., Bach C., Zeisig D., Garcia-Cuellar M.P., Monroe S., Sreekumar A., Zhou R., Nesvizhskii A., Chinnaiyan A., Hess J.L., Slany R.K. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood 2007, 110:4445-4454.
33. Muntean A.G., Tan J., Sitwala K., Huang Y., Bronstein J., Connelly J.A., Basrur V., Elenitoba-Johnson K.S., Hess J.L. The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis. Cancer Cell 2010, 17:609-621.
34. Nakamura T., Mori T., Tada S., Krajewski W., Rozovskaia T., Wassell R., Dubois G., Mazo A., Croce C.M., Canaani E. ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol. Cell 2002, 10:1119-1128.
35. Narla G., Heath K.E., Reeves H.L., Li D., Giono L.E., Kimmelman A.C., Glucksman M.J., Narla J., Eng F.J., Chan A.M., et al. KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 2001, 294:2563-2566.
36. Ohyashiki K., Kocova M., Ryan D.H., Rowe J.M., Sandberg A.A. Secondary acute myeloblastic leukemia with a Ph translocation in a treated Wegener's granulomatosis. Cancer Genet. Cytogenet. 1986, 19:331-333.
37. Okada Y., Feng Q., Lin Y., Jiang Q., Li Y., Coffield V.M., Su L., Xu G., Zhang Y. hDOT1L links histone methylation to leukemogenesis. Cell 2005, 121:167-178.
38. Patel S.R., Kim D., Levitan I., Dressler G.R. The BRCT-domain containing protein PTIP links PAX2 to a histone H3, lysine 4 methyltransferase complex. Dev. Cell 2007, 13:580-592.
39. Patel A., Dharmarajan V., Cosgrove M.S. Structure of WDR5 bound to mixed lineage leukemia protein-1 peptide. J. Biol. Chem. 2008, 283:32158-32161.
40. Senisterra G., Wu H., Allali-Hassani A., Wasney G.A., Barsyte-Lovejoy D., Dombrovski L., Dong A., Nguyen K.T., Smil D., Bolshan Y., et al. Small-molecule inhibition of MLL activity by disruption of its interaction with WDR5. Biochem. J. 2013, 449:151-159.
41. Song J.J., Kingston R.E. WDR5 interacts with mixed lineage leukemia (MLL) protein via the histone H3-binding pocket. J. Biol. Chem. 2008, 283:35258-35264.
42. Terranova R., Agherbi H., Boned A., Meresse S., Djabali M. Histone and DNA methylation defects at Hox genes in mice expressing a SET domain-truncated form of Mll. Proc. Natl. Acad. Sci. USA 2006, 103:6629-6634.
43. Thiel A.T., Blessington P., Zou T., Feather D., Wu X., Yan J., Zhang H., Liu Z., Ernst P., Koretzky G.A., Hua X. MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele. Cancer Cell 2010, 17:148-159.
44. Trievel R.C., Shilatifard A. WDR5, a complexed protein. Nat. Struct. Mol. Biol. 2009, 16:678-680.
45. Wu L., Lee S.Y., Zhou B., Nguyen U.T., Muir T.W., Tan S., Dou Y. ASH2L regulates ubiquitylation signaling to MLL: trans-regulation of H3 K4 methylation in higher eukaryotes. Mol. Cell 2013, 49:1108-1120.
46. Wysocka J., Swigut T., Milne T.A., Dou Y., Zhang X., Burlingame A.L., Roeder R.G., Brivanlou A.H., Allis C.D. WDR5 associates with histone H3 methylated at K4 and is essential for H3 K4 methylation and vertebrate development. Cell 2005, 121:859-872.
47. Yokoyama A., Lin M., Naresh A., Kitabayashi I., Cleary M.L. A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell 2010, 17:198-212.
48. Yu B.D., Hess J.L., Horning S.E., Brown G.A., Korsmeyer S.J. Altered Hox expression and segmental identity in Mll-mutant mice. Nature 1995, 378:505-508.
49. Zuber J., Shi J., Wang E., Rappaport A.R., Herrmann H., Sison E.A., Magoon D., Qi J., Blatt K., Wunderlich M., et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011, 478:524-528.